Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution

The concept of agnostic therapy. Some tumor vulnerabilities are shared across various cancer types; therefore, their targeting is potentially effective irrespective of the histological origin of a given malignancy. Activating mutations in kinases involved in the MAPK signaling pathway are the best established agnostic targets. High tumor mutation burden, which may be caused by external carcinogens, errors in DNA repair pathways, or alterations in DNA polymerases, is associated with increased tumor antigenicity and, therefore, its sensitivity to immune therapy. Homologous recombination deficiency may be attributed to the inactivation of BRCA1/2 or some other genes; it renders tumor responsiveness to DNA double-strand-break-inducing drugs.
Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution

Publication

Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution. (2024) Svetlana N. Aleksakhina, et al. Int J Mol Sci. 2024 Apr;25(7):4094. Figure: F1.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates BRAF BRAF ncbigene_symbol BRAF 673
Homo sapiens Primates NTRK1-3 NTRK2 ncbigene_symbol NTRK2 4915
Homo sapiens Primates NTRK1-3 NTRK3 ncbigene_symbol NTRK3 4916
Homo sapiens Primates NTRK1-3 NTRK1 ncbigene_symbol NTRK1 4914
Homo sapiens Primates RET RET ncbigene_symbol RET 5979
Homo sapiens Primates polymerases POLYMERASE ncbigene_synonym ERVK-9 100616102
Homo sapiens Primates polymerases POLYMERASE ncbigene_synonym ERVK-11 100862688
Homo sapiens Primates polymerases POLYMERASE ncbigene_synonym ERVK-19 105376906
Homo sapiens Primates HRD HRD ncbigene_synonym TBCE 6905
Homo sapiens Primates BRCA1/2inactivation BRCA1 ncbigene_symbol BRCA1 672

Chemical mentions

Word Match MeSH Name ChEBI

Disease mentions

Word Match MeSH Name DOID